HK1119942A1 - Dissolution aids for oral peptide delivery comprising a biguanide - Google Patents

Dissolution aids for oral peptide delivery comprising a biguanide

Info

Publication number
HK1119942A1
HK1119942A1 HK08113450.8A HK08113450A HK1119942A1 HK 1119942 A1 HK1119942 A1 HK 1119942A1 HK 08113450 A HK08113450 A HK 08113450A HK 1119942 A1 HK1119942 A1 HK 1119942A1
Authority
HK
Hong Kong
Prior art keywords
biguanide
dissolution aids
peptide delivery
oral peptide
oral
Prior art date
Application number
HK08113450.8A
Other languages
English (en)
Inventor
Roger R C New
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Publication of HK1119942A1 publication Critical patent/HK1119942A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08113450.8A 2006-02-17 2008-12-10 Dissolution aids for oral peptide delivery comprising a biguanide HK1119942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0603252.8A GB0603252D0 (en) 2006-02-17 2006-02-17 Dissolution aids for oral peptide delivery
PCT/GB2007/000539 WO2007093806A1 (en) 2006-02-17 2007-02-16 Dissolution aids for oral peptide delivery comprising a biguanide

Publications (1)

Publication Number Publication Date
HK1119942A1 true HK1119942A1 (en) 2009-03-20

Family

ID=36142051

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113450.8A HK1119942A1 (en) 2006-02-17 2008-12-10 Dissolution aids for oral peptide delivery comprising a biguanide

Country Status (20)

Country Link
US (2) US20090041849A1 (xx)
EP (1) EP1986678B1 (xx)
JP (1) JP5306829B2 (xx)
KR (1) KR101482279B1 (xx)
CN (1) CN101384275B (xx)
AU (1) AU2007216302B2 (xx)
BR (1) BRPI0707866A2 (xx)
CA (1) CA2642847C (xx)
CY (1) CY1115150T1 (xx)
DK (1) DK1986678T3 (xx)
ES (1) ES2444573T3 (xx)
GB (1) GB0603252D0 (xx)
HK (1) HK1119942A1 (xx)
IL (1) IL193442A (xx)
NZ (1) NZ570525A (xx)
PT (1) PT1986678E (xx)
RU (1) RU2433830C2 (xx)
SI (1) SI1986678T1 (xx)
WO (1) WO2007093806A1 (xx)
ZA (1) ZA200807016B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
WO2011017335A1 (en) 2009-08-03 2011-02-10 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
EP2515992B1 (en) * 2009-12-24 2018-10-10 Rani Therapeutics, LLC Swallowable drug delivery device
JP5931757B2 (ja) * 2010-03-10 2016-06-08 インキューブ ラブズ， エルエルシー 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物
WO2011159100A2 (ko) * 2010-06-15 2011-12-22 한올바이오파마주식회사 항암 활성을 나타내는 약제학적 조성물
KR101275258B1 (ko) * 2010-06-15 2013-06-17 한올바이오파마주식회사 항암 활성을 나타내는 약제학적 조성물
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8764733B2 (en) 2010-12-23 2014-07-01 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3653224A1 (en) * 2011-06-29 2020-05-20 Rani Therapeutics, LLC Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2014059522A1 (en) 2012-10-17 2014-04-24 Methylation Sciences International Srl Compositions comprising s-adenosylmethionine and a gallic acid ester
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
MX2019013747A (es) 2017-05-17 2020-07-20 Massachusetts Inst Technology Sistemas autoenderezables y componentes y métodos relacionados.
US11432545B2 (en) 2017-06-05 2022-09-06 Arxada, LLC Fast kill disinfectant wiping composition and premoistened wipes made from same
BR112020006587B1 (pt) * 2017-10-06 2024-01-09 Cargill, Incorporated Solução aquosa de glicosídeo de esteviol, composição de bebida, adoçante, e, método para solubilizar uma composição total de glicosídeo de esteviol
BR112020006798A2 (pt) 2017-10-06 2020-10-06 Cargill, Incorporated composição de glicosídeo de esteviol com prolongamento de doçura reduzido, e, método para reduzir o prolongamento da doçura a partir de um glicosídeo de esteviol em uma composição comestível.
WO2019222570A1 (en) 2018-05-17 2019-11-21 Massachusetts Institute Of Technology Systems for electrical stimulation
TR201820952A2 (tr) * 2018-12-28 2020-07-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Granülosi̇t koloni̇ uyarici faktör i̇çeren bi̇r kombi̇nasyon
US11771829B2 (en) 2019-02-01 2023-10-03 Massachusetts Institute Of Technology Systems and methods for liquid injection
WO2020210118A1 (en) 2019-04-06 2020-10-15 Cargill, Incorporated Sensory modifiers
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
CN113209280B (zh) * 2021-03-07 2022-03-25 合肥天汇孵化科技有限公司 甲状旁腺激素组合物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
DE2946955A1 (de) 1979-11-21 1981-05-27 Bayer Ag, 5090 Leverkusen Verfahren zum anordnen von einbauten in gutfuehrungsrohre von waermebehandlungseinrichtungen fuer pulvirges bis koerniges, rieselfaehiges, ggf. angeschlaemmtes gut
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
JPH08505149A (ja) * 1992-12-28 1996-06-04 ジェイ． ベイリンク，デビッド 骨再吸収検定法
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
EP1520582A3 (en) * 1998-02-02 2009-07-01 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
US6261844B1 (en) * 1998-12-17 2001-07-17 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Urine preservative
BR0013813A (pt) 2000-09-18 2002-04-30 Rpg Life Sciences Ltd Formulação auto-emulsificável possuindo atividades bioabsorventes e imunossupressoras
GB2368792A (en) * 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
FR2858232B1 (fr) * 2003-07-29 2006-03-03 Pierre Potier Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
CN1942194B (zh) * 2004-04-29 2010-05-26 伊莱利利公司 多杀菌素在制备用于伤口愈合的药物中的用途
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
CN105641686A (zh) * 2005-09-19 2016-06-08 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形

Also Published As

Publication number Publication date
GB0603252D0 (en) 2006-03-29
JP2009526827A (ja) 2009-07-23
CN101384275A (zh) 2009-03-11
DK1986678T3 (da) 2014-02-03
US20120177602A1 (en) 2012-07-12
WO2007093806A1 (en) 2007-08-23
CA2642847C (en) 2015-01-06
AU2007216302B2 (en) 2011-11-10
AU2007216302A1 (en) 2007-08-23
NZ570525A (en) 2010-07-30
IL193442A (en) 2015-08-31
ZA200807016B (en) 2009-10-28
JP5306829B2 (ja) 2013-10-02
PT1986678E (pt) 2014-02-12
KR20090038389A (ko) 2009-04-20
CA2642847A1 (en) 2007-08-23
BRPI0707866A2 (pt) 2011-05-10
CY1115150T1 (el) 2016-12-14
RU2433830C2 (ru) 2011-11-20
US9987232B2 (en) 2018-06-05
ES2444573T3 (es) 2014-02-25
WO2007093806A8 (en) 2008-10-02
US20090041849A1 (en) 2009-02-12
IL193442A0 (en) 2011-08-01
RU2008137146A (ru) 2010-03-27
EP1986678A1 (en) 2008-11-05
EP1986678B1 (en) 2013-11-13
KR101482279B1 (ko) 2015-01-13
SI1986678T1 (sl) 2014-04-30
CN101384275B (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
HK1119942A1 (en) Dissolution aids for oral peptide delivery comprising a biguanide
EP2152195A4 (en) PHARMACEUTICAL PEPTIDE FOR ORAL ADMINISTRATION
IL198911A0 (en) Drug delivery
GB2439061B (en) A dispenser
EP2026709A4 (en) FLOW-MEDIATED DELIVERY FROM A MEDICINAL MASS
PL1924151T3 (pl) Systemy dostarczania doustnego o kontrolowanym uwalnianiu
GB0712060D0 (en) A dispenser system
PL2058020T3 (pl) Urządzenie do podawania leków
ZA200807006B (en) Drug delivery device
IL183295A0 (en) Drug delivery device
ZA200901175B (en) Drug dispenser
HK1134047A1 (en) A delivery system and process
GB0402736D0 (en) A drug delivery device
ZA200707513B (en) Dispenser for delivering medicament
PL2340809T3 (pl) Lek zawierający fluorochinoliny
ZA200901093B (en) Drug dispenser
IL195525A (en) A vaccine that contains a replicin peptide
EP1858493A4 (en) SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
ZA200804176B (en) A delivery system
IL198698A0 (en) Pharmaceutical compositions comprising a bisphosphonate compound
EP1977766A4 (en) DRUG DELIVERY MATERIAL
ZA200710786B (en) A heterogeneously configured multiparticulate gastrointestinal drug delivery system
GB0606093D0 (en) Prosthesis delivery system
GB0605042D0 (en) A Peptide
TWI340043B (en) Oral drug delivery system

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190214